Drugs / LEVI-04
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03227796 | Jul 2017 → Mar 2021 | osteoarthritis | Levicept | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05618782 Comparator | Oct 2022 → May 2024 | osteoarthritis, knee, rheumatic disorder | Levicept | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-07 | Levicept | Results Positive Data from Levicept’s Phase II Study of LEVI-04 levicept.com ↗
Results from a Randomised Controlled Phase II Trial with LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrate Substantially Improved Pain and Function Without Deleterious Effects on Joint Structure in People With Knee Osteoarthritis |
| 2024-08-06 | Levicept | Results Levicept announces positive results of Phase II Trial of novel Neurotrophic-3 Inhibitor, LEVI-04, for the Treatment of Patients with Moderate to Severe Osteoarthritis. levicept.com ↗ |
All press releases naming this drug 4 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEVI-04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05618782 ↗ |
| Action | Inhibit | “LEVI-04 is a p75 neurotrophin receptor (p75NTR) fusion protein that inhibits neurotrophin-3.” PMID 41905364 ↗ Mar 2026 |
| Modality | Protein / enzyme biologic | “LEVI-04, a fully human chimeric fusion protein that combines the Fc fragment of human immunoglobulin G1 with the p75 neurotrophin receptor (p75 NTR)” NCT05618782 ↗ |
| Route | Intravenous | “Each dose will be administered as an intravenous infusion over 30 minutes.” NCT03227796 ↗ |
| Target | NTF3 | “LEVI-04 is a p75 neurotrophin receptor (p75NTR) fusion protein that inhibits neurotrophin-3.” PMID 41905364 ↗ Mar 2026 |